Unresectable Hepatocellular Carcinoma: Global Market Forecast at $2.64 Billion by 2028, Dominated by Pfizer, Johnson & Johnson, Roche, Merck & Co, and Bayer
May 07, 2024 12:33 ET
|
Research and Markets
Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Unresectable Hepatocellular Carcinoma Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The global unresectable...
Metastatic Liver Cancer Pipeline Insight 2024, Featuring Key Players Oncorus, Sirnaomics, Codiak BioSciences, RemeGen, Amarin, Medivir, AstraZeneca, Amal Therapeutics and Boehringer Ingelheim
April 15, 2024 07:20 ET
|
Research and Markets
Dublin, April 15, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Liver Cancer - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The report provides...
Global Liver Cancer Drug Market to Reach USD 7.83 Billion by 2030: Innovative treatments like oncolytic viruses and RNA interference (RNAi) have gained market traction
April 10, 2024 04:04 ET
|
Research and Markets
Dublin, April 10, 2024 (GLOBE NEWSWIRE) -- The "Liver Cancer Drug Market Size, Share & Trends Analysis Report By Drug Class (Targeted Therapy, Immunotherapy, Chemotherapy), By Region, And...
Doxorubicin Global Strategic Research Report 2024: Market to Reach $1.7 Billion by 2030 from $1.1 Billion in 2023, Driven by Rise in Cancer Incidence and Innovations in Cancer Drug Delivery
April 05, 2024 09:07 ET
|
Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Doxorubicin - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Doxorubicin Market to Reach $1.7...
Nivolumab Market Forecasts Indicate Robust Growth Driven by Advances in Cancer Immunotherapy and Increased Global Access to Care
February 15, 2024 14:57 ET
|
Research and Markets
Dublin, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The "Nivolumab Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Recent advancements in cancer treatment and the...
Global Hepatocellular Carcinoma Clinical Trials Review 2023: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
January 31, 2024 06:58 ET
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Hepatocellular Carcinoma - Global Clinical Trials Review, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial...
MTG201 + Nivolumab Drug and Market Analysis 2023-2032: Sales Analytics, Clinical Assessment, SWOT Analysis, Emerging Competitors
January 30, 2024 10:50 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "MTG201 + nivolumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides...
Regorafenib Drug and Market Analysis 2023-2032 with Forecasted Sales Data
January 30, 2024 10:45 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Regorafenib Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report offers a comprehensive...
Bile Duct Cancer Treatment Market Trends and Forecast 2031 - Market Set for Significant Growth by 2031 Amid Rising Incidences and Technological Advancements
January 09, 2024 04:28 ET
|
Research and Markets
Dublin, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The "Bile Duct Cancer Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade,...
Ipilimumab + nivolumab Drug Insight and Market Forecast - 2032
December 14, 2023 10:08 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Ipilimumab + nivolumab Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...